In the relapsing–remitting EAE (RR‐EAE) mouse model, inhibiting NLRP3 inflammasome activation may be a potential therapeutic approach to alleviate central nervous system (CNS) pathological pain (CPP) and disease relapse in RR‐MS mice [44]. This evidence concerns the gene NLRP3 and myeloid sarcoma.